EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Variant Allelic Frequency to Track Therapy Response and Evaluate Leptomeningeal Disease in Metastatic Central Nervous System Cancers

Vindhya Udhane, Alexandra Larson, Jennifer N Adams iD, Rakshitha Jagadish, Anthony Acevedo, Brett A Domagala iD, Samantha A Vo, Tarin Peltier, Daniel Sanchez, Viriya Keo iD, Julianna Ernst, Kala F Schilter und 2 weitere

Diagnostics · 13.03.2026 · 16 (6) · 851

DOI: 10.3390/diagnostics16060851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 13.03.2026. Verfasst von Vindhya Udhane und 13 weiteren Autor:innen. Beteiligte Einrichtung: Belay Diagnostics, Suite 530, 1375 W. Fulton St, Chicago, IL 60607, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnosis of leptomeningeal disease (LMD) remains a clinical challenge due to nonspecific neurological symptoms, limitations of imaging, and the low sensitivity of cerebrospinal fluid (CSF) cytology. Molecular biomarkers, such as circulating tumor DNA (ctDNA) variant allele frequencies (VAFs), offer potential for improved detection and disease monitoring.

Methods

Gene-level VAFs were analyzed from 118 Summit™ positive CSF specimens and evaluated in the context of clinical diagnosis, neurological presentation, neuroimaging, and CSF cytology. Longitudinal analyses were performed on serial CSF samples to assess VAF dynamics following therapy.

Results

Longitudinal assessment demonstrated that decreases in VAF post-treatment aligned with clinical stabilization, whereas rising or persistent VAFs reflected disease progression, therapeutic resistance, or evolving clonal mutations. Elevated VAFs correlated strongly with clinically confirmed LMD and were concordant with radiographic and clinical indicators of disease.

Conclusions

VAF analysis in CSF provides a quantitative biomarker for the detection and monitoring of metastatic CNS disease. These findings support its utility as a complementary tool to conventional diagnostics, offering real-time insights into disease burden, therapeutic response, and clonal evolution in LMD.

Schlagwörter

Stichwörter der Autor:innen

CSF liquid biopsySummit™leptomeningeal diseaselongitudinal analysisvariant allele frequency

Autor:innen und Institutionen

  • Belay Diagnostics, Suite 530, 1375 W. Fulton St, Chicago, IL 60607, USA.

ORCID-Profile: Jennifer N Adams, Brett A Domagala, Viriya Keo, Honey V Reddi

Zitieren

APA

Udhane, V., Larson, A., Adams, J. N., Jagadish, R., Acevedo, A., Domagala, B. A., Vo, S. A., Peltier, T., Sanchez, D., Keo, V., Ernst, J., Schilter, K. F., Nie, Q., & Reddi, H. V. (2026). Variant Allelic Frequency to Track Therapy Response and Evaluate Leptomeningeal Disease in Metastatic Central Nervous System Cancers. Diagnostics, 16(6), 851. https://doi.org/10.3390/diagnostics16060851

Vancouver

Udhane V, Larson A, Adams JN, Jagadish R, Acevedo A, Domagala BA, et al. Variant Allelic Frequency to Track Therapy Response and Evaluate Leptomeningeal Disease in Metastatic Central Nervous System Cancers. Diagnostics. 2026;16(6):851. doi:10.3390/diagnostics16060851

BibTeX
@article{Udhane2026,
  author = {Udhane, Vindhya and Larson, Alexandra and Adams, Jennifer N and Jagadish, Rakshitha and Acevedo, Anthony and Domagala, Brett A and Vo, Samantha A and Peltier, Tarin and Sanchez, Daniel and Keo, Viriya and Ernst, Julianna and Schilter, Kala F and Nie, Qian and Reddi, Honey V},
  title = {Variant Allelic Frequency to Track Therapy Response and Evaluate Leptomeningeal Disease in Metastatic Central Nervous System Cancers},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {851},
  doi = {10.3390/diagnostics16060851}
}
Kostenlos starten →